RyR2 inhibitors such as EL20 directly target the disease‐causing molecular defect in patients with CPVT (ie leaky RyR2 channels) and could be more effective compared to beta blockers that work upstream in the beta‐adrenergic receptor signalling pathway that leads to RyR2 phosphorylation and exacerbation of SR Ca2+ leak during stress or exercise.31 This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.